Blood-level and safety study of LY4174794 in adults who are overweight or obese
Official title: A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Run by Eli Lilly and Company · NCT07654972 · Data updated 2026-11-12
This study tests how safe LY4174794 is and how it behaves in the body of adults who are overweight or obese but otherwise healthy.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 116 (estimated) |
| Sponsor | Eli Lilly and Company Industry-sponsored |
| Locations | 3 sites (San Antonio, Texas and 2 other locations) |
| Status | Recruiting |
| Started | June 24, 2026 |
| Main results expected | April 2029 |
| Study ends | April 2029 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07654972 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with BMI ≥27 kg/m² and overweight or BMI ≥30 kg/m² obesity who are otherwise healthy and have had stable weight for at least 3 months.
✕Probably not a fit
Individuals with significant cardiovascular, hepatic, renal, or other disorders that could affect drug handling or safety may not benefit and are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1 interventional study to assess the safety, tolerability, and pharmacokinetics of LY4174794 in adults with overweight or obesity who do not have major comorbidities. Participants will receive LY4174794 or placebo, with blood tests to measure drug levels and how long the drug stays in the bloodstream. The study duration is approximately 30 to 39 weeks, including screening, treatment, and follow-up. Key exclusions include cardiovascular, hepatic, renal, or other conditions that could affect drug absorption or safety. The trial is led by Eli Lilly and conducted at sites in San Antonio, Salt Lake City, and Singapore.
Why it matters
Potential benefit: If successful, participants may gain access to a well-tolerated dose range and contribute to knowledge about how the drug behaves in the body for overweight or obese individuals.
How similar studies have gone: Prior Phase 1 pharmacokinetic studies in similar populations have shown measurable drug exposure and tolerability signals for LY4174794 in early-stage research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-reported stable weight for 3 months prior to screening Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data * Is an individual of childbearing potential (IOCBP)
Where it's running
-
ICON Early Phase Services, LLC
San Antonio, Texas, United States Recruiting -
ICON Early Phase Services, LLC
Salt Lake City, Utah, United States Not yet recruiting -
Lilly Centre for Clinical Pharmacology
Singapore, Singapore Not yet recruiting
Study contacts
- Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Email: LillyTrials@Lilly.com
- Phone: 1-317-615-4559
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese
This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.
-
FutureShape Family: a family-based weight-management program with semaglutide for children and parents
This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.
-
Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese
This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.